{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:11:58Z","timestamp":1785413518138,"version":"3.56.0"},"posted":{"date-parts":[[2026,2,6]]},"group-title":"Cancer Biology","reference-count":97,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"award":["ASP241264627"],"award-info":[{"award-number":["ASP241264627"]}],"id":[{"id":"https:\/\/ror.org\/02nadbe75","id-type":"ROR","asserted-by":"publisher"}]},{"award":["SAC232150"],"award-info":[{"award-number":["SAC232150"]}],"id":[{"id":"https:\/\/ror.org\/02nadbe75","id-type":"ROR","asserted-by":"publisher"}]},{"award":["RO1CA148761-15"],"award-info":[{"award-number":["RO1CA148761-15"]}],"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,2,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:p>Triple-negative breast cancer (TNBC) has high rates of recurrence despite chemotherapy and immune checkpoint blockade (ICB). Tumor-associated macrophages (TAMs) can either suppress or support anti-tumor immunity, but the mechanisms governing these states and therapeutic targets remain unclear. Here, integrating public scRNAseq datasets with TNBC cohorts, we identify a prognostic myeloid signature defined by CXCL9hi\/C1Qlow TAM programs, associated with improved survival and increased lymphocyte activation pathways. Using immunocompetent p53-null syngeneic TNBC models spanning basal-like (2153L) and claudin-low (T12) subtypes, we show that immunomodulatory cyclophosphamide (CTX) reprograms hematopoiesis toward the monocytic lineage and induces an interferon (IFN) conditioned tumor milieu that supports CXCL9\u207a monocyte-derived macrophages (Mo.Macs) in basal-like disease. Combining CTX with the next generation MERTK-selective inhibitor UNC2371 (MRX-2843) drives complete remissions in both models, but durable long-term responses occurred selectively in the basal-like subtype model. The expansion of antigen-presenting CXCL9\u207a Mo.Macs and reduction of C1q\u207a phagocytic TAMs are observed in responding tumors. Mechanistically, MERTK inhibition relieves MAPK\/SOCS1 mediated restraint of IFN signaling driving a positive feedback loop of IRF7\/STAT1\/IRF1 driven CXCL9 induction. Functionally, tumor control requires CXCL9-CXCR3 dependent CD4\u207a T cell recruitment, accumulation of stem-like memory CD4\u207a T cells, and germinal center like immune organization in tumor-draining lymph nodes. PD-1 blockade further increases durability, preventing recurrence in most treated basal-like tumors. Together, these findings define an IFN licensed, MERTK regulated myeloid checkpoint that can be therapeutically targeted to convert suppressive TNBC microenvironments into durable adaptive immunity, supporting clinical translation of CTX + MRX-2843 based combinations in basal-like TNBC.<\/jats:p>\n                <jats:sec>\n                  <jats:title>Significance<\/jats:title>\n                  <jats:p>Suppressive myeloid programing limits effective adaptive immune engagement in TNBC usually resulting in ICB treatment resistance and tumor recurrence. This study identifies a therapeutically actionable myeloid interferon checkpoint in which MERTK inhibition stabilizes CXCL9\u207a monocyte-macrophage programming to promote CD4\u207a T cell dependent immune memory and durable tumor control in basal-like TNBC.<\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2026.02.04.703648","type":"posted-content","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T05:06:23Z","timestamp":1770440783000},"source":"Crossref","is-referenced-by-count":0,"title":["MERTK inhibition cooperates with immunomodulatory cyclophosphamide to induce CXCL9\u207a monocyte-macrophage programming and durable anti-tumor immunity in triple negative breast cancer"],"prefix":"10.64898","author":[{"given":"Alex J.","family":"Smith","sequence":"first","affiliation":[{"name":"Department of Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA"},{"name":"Cell and Cancer Biology, Graduate School of Biomedical Sciences, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA"},{"name":"Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Schrank","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina, 125 Mason Farm Road, Chapel Hill, NC 27599, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA"},{"name":"Cell and Cancer Biology, Graduate School of Biomedical Sciences, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA"},{"name":"Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego A.","family":"Pedroza","sequence":"additional","affiliation":[{"name":"Department of Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA"},{"name":"Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Calderon","sequence":"additional","affiliation":[{"name":"Department of Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueying","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA"},{"name":"Cell and Cancer Biology, Graduate School of Biomedical Sciences, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA"},{"name":"Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA"},{"name":"Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Gabriel","sequence":"additional","affiliation":[{"name":"Department of Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA"},{"name":"Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Rivas","sequence":"additional","affiliation":[{"name":"Department of Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA"},{"name":"Cell and Cancer Biology, Graduate School of Biomedical Sciences, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA"},{"name":"Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengshuo","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA"},{"name":"Cell and Cancer Biology, Graduate School of Biomedical Sciences, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA"},{"name":"Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Serody","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina, 125 Mason Farm Road, Chapel Hill, NC 27599, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles M.","family":"Perou","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina, 125 Mason Farm Road, Chapel Hill, NC 27599, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Shelton","family":"Earp","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina, 125 Mason Farm Road, Chapel Hill, NC 27599, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Rosen","sequence":"additional","affiliation":[{"name":"Department of Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA"},{"name":"Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026021010301636000_2026.02.04.703648v1.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21863"},{"key":"2026021010301636000_2026.02.04.703648v1.2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21871"},{"key":"2026021010301636000_2026.02.04.703648v1.3","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3896"},{"key":"2026021010301636000_2026.02.04.703648v1.4","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-19-0035"},{"key":"2026021010301636000_2026.02.04.703648v1.5","doi-asserted-by":"publisher","DOI":"10.1172\/JCI45014"},{"key":"2026021010301636000_2026.02.04.703648v1.6","doi-asserted-by":"crossref","unstructured":"Kesireddy M , Elsayed L , Shostrom VK , Agarwal P , Asif S , Yellala A , et al. Overall Survival and Prognostic Factors in Metastatic Triple-Negative Breast Cancer: A National Cancer Database Analysis. Cancers (Basel). 2024;16(10).","DOI":"10.3390\/cancers16101791"},{"key":"2026021010301636000_2026.02.04.703648v1.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202809"},{"key":"2026021010301636000_2026.02.04.703648v1.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409932"},{"key":"2026021010301636000_2026.02.04.703648v1.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028485"},{"issue":"19","key":"2026021010301636000_2026.02.04.703648v1.10","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa2511734","article-title":"Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer","volume":"393","year":"2025","journal-title":"N Engl J Med"},{"key":"2026021010301636000_2026.02.04.703648v1.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1876-x"},{"key":"2026021010301636000_2026.02.04.703648v1.12","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954"},{"key":"2026021010301636000_2026.02.04.703648v1.13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0144"},{"key":"2026021010301636000_2026.02.04.703648v1.14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13329-5"},{"key":"2026021010301636000_2026.02.04.703648v1.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.02.009"},{"issue":"1","key":"2026021010301636000_2026.02.04.703648v1.16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41698-024-00522-z","article-title":"Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance","volume":"8","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"2026021010301636000_2026.02.04.703648v1.17","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2014.00075"},{"key":"2026021010301636000_2026.02.04.703648v1.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.01.007"},{"key":"2026021010301636000_2026.02.04.703648v1.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.03.014"},{"key":"2026021010301636000_2026.02.04.703648v1.20","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-023-01061-6"},{"key":"2026021010301636000_2026.02.04.703648v1.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.06.010"},{"key":"2026021010301636000_2026.02.04.703648v1.22","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1937"},{"key":"2026021010301636000_2026.02.04.703648v1.23","doi-asserted-by":"publisher","DOI":"10.1038\/nri3175"},{"key":"2026021010301636000_2026.02.04.703648v1.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2014.09.006"},{"key":"2026021010301636000_2026.02.04.703648v1.25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1868"},{"key":"2026021010301636000_2026.02.04.703648v1.26","doi-asserted-by":"publisher","DOI":"10.1126\/science.1198443"},{"key":"2026021010301636000_2026.02.04.703648v1.27","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203270"},{"key":"2026021010301636000_2026.02.04.703648v1.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.08.008"},{"key":"2026021010301636000_2026.02.04.703648v1.29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1018862108"},{"key":"2026021010301636000_2026.02.04.703648v1.30","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-019-0373-7"},{"key":"2026021010301636000_2026.02.04.703648v1.31","doi-asserted-by":"publisher","DOI":"10.1002\/stem.1752"},{"key":"2026021010301636000_2026.02.04.703648v1.32","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-1101"},{"key":"2026021010301636000_2026.02.04.703648v1.33","doi-asserted-by":"crossref","unstructured":"Yuan X , Hao X , Chan HL , Zhao N , Pedroza DA , Liu F , et al. CREB-binding protein\/P300 bromodomain inhibition reduces neutrophil accumulation and activates antitumor immunity in triple-negative breast cancer. JCI Insight. 2024;9(20).","DOI":"10.1172\/jci.insight.182621"},{"key":"2026021010301636000_2026.02.04.703648v1.34","doi-asserted-by":"crossref","unstructured":"Zhao N , Kabotyanski EB , Saltzman AB , Malovannaya A , Yuan X , Reineke LC , et al. Targeting eIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer. J Clin Invest. 2023;133(24).","DOI":"10.1172\/JCI172503"},{"key":"2026021010301636000_2026.02.04.703648v1.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.12.031"},{"key":"2026021010301636000_2026.02.04.703648v1.36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24545-3"},{"issue":"5","key":"2026021010301636000_2026.02.04.703648v1.37","doi-asserted-by":"crossref","first-page":"189163","DOI":"10.1016\/j.bbcan.2024.189163","article-title":"Leveraging preclinical models of metastatic breast cancer","volume":"1879","year":"2024","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"2026021010301636000_2026.02.04.703648v1.38","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2017.206"},{"key":"2026021010301636000_2026.02.04.703648v1.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2014.11.017"},{"key":"2026021010301636000_2026.02.04.703648v1.40","doi-asserted-by":"crossref","unstructured":"Pedroza DA , Yuan X , Liu F , Chan HL , Zhang C , Bowie W , et al. Anti-CSF-1R therapy with combined immuno-chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched triple negative breast cancers. Nat Commun. 2026.","DOI":"10.1101\/2025.04.30.651522"},{"key":"2026021010301636000_2026.02.04.703648v1.41","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0397"},{"key":"2026021010301636000_2026.02.04.703648v1.42","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00813-7"},{"key":"2026021010301636000_2026.02.04.703648v1.43","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3847"},{"key":"2026021010301636000_2026.02.04.703648v1.44","doi-asserted-by":"publisher","DOI":"10.1038\/35075603"},{"key":"2026021010301636000_2026.02.04.703648v1.45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-021634"},{"key":"2026021010301636000_2026.02.04.703648v1.46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209031"},{"key":"2026021010301636000_2026.02.04.703648v1.47","doi-asserted-by":"publisher","DOI":"10.1172\/JCI39325"},{"key":"2026021010301636000_2026.02.04.703648v1.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.10.034"},{"issue":"2","key":"2026021010301636000_2026.02.04.703648v1.49","doi-asserted-by":"crossref","first-page":"101415","DOI":"10.1016\/j.xcrm.2024.101415","article-title":"Disruption of MerTK increases the efficacy of checkpoint inhibitor by enhancing ferroptosis and immune response in hepatocellular carcinoma","volume":"5","year":"2024","journal-title":"Cell Rep Med"},{"key":"2026021010301636000_2026.02.04.703648v1.50","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08225-y"},{"issue":"3","key":"2026021010301636000_2026.02.04.703648v1.51","doi-asserted-by":"crossref","first-page":"100554","DOI":"10.1016\/j.xcrm.2022.100554","article-title":"AXL targeting restores PD-1 blockade sensitivity of STK11\/LKB1 mutant NSCLC through expansion of TCF1(+) CD8 T cells","volume":"3","year":"2022","journal-title":"Cell Rep Med"},{"key":"2026021010301636000_2026.02.04.703648v1.52","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00846-8"},{"key":"2026021010301636000_2026.02.04.703648v1.53","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107577"},{"key":"2026021010301636000_2026.02.04.703648v1.54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1244170"},{"issue":"3","key":"2026021010301636000_2026.02.04.703648v1.55","first-page":"e85630","article-title":"The MERTK\/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia","volume":"1","year":"2016","journal-title":"JCI Insight"},{"key":"2026021010301636000_2026.02.04.703648v1.56","doi-asserted-by":"crossref","unstructured":"Lee-Sherick AB , Jacobsen KM , Henry CJ , Huey MG , Parker RE , Page LS , et al. MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity. JCI Insight. 2020;5(23).","DOI":"10.1172\/jci.insight.145847"},{"key":"2026021010301636000_2026.02.04.703648v1.57","doi-asserted-by":"crossref","unstructured":"Yan D , Earp HS , DeRyckere D , Graham DK . Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer. Cancers (Basel). 2021;13(22).","DOI":"10.3390\/cancers13225639"},{"issue":"1","key":"2026021010301636000_2026.02.04.703648v1.58","first-page":"vdaa065","article-title":"MerTK inhibition decreases immune suppressive glioblastoma-associated macrophages and neoangiogenesis in glioblastoma microenvironment","volume":"2","year":"2020","journal-title":"Neurooncol Adv"},{"issue":"1","key":"2026021010301636000_2026.02.04.703648v1.59","doi-asserted-by":"crossref","first-page":"5292","DOI":"10.1038\/s41467-024-49667-2","article-title":"Co-targeting JAK1\/STAT6\/GAS6\/TAM signaling improves chemotherapy efficacy in Ewing sarcoma","volume":"15","year":"2024","journal-title":"Nat Commun"},{"issue":"9","key":"2026021010301636000_2026.02.04.703648v1.60","doi-asserted-by":"crossref","first-page":"108115","DOI":"10.1016\/j.celrep.2020.108115","article-title":"Baseline Frequency of Inflammatory Cxcl9-Expressing Tumor-Associated Macrophages Predicts Response to Avelumab Treatment","volume":"32","year":"2020","journal-title":"Cell Rep"},{"key":"2026021010301636000_2026.02.04.703648v1.61","doi-asserted-by":"publisher","DOI":"10.1126\/science.ade2292"},{"key":"2026021010301636000_2026.02.04.703648v1.62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.04.011"},{"issue":"7","key":"2026021010301636000_2026.02.04.703648v1.63","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.trecan.2022.02.006","article-title":"C1q+ macrophages: passengers or drivers of cancer progression","volume":"8","year":"2022","journal-title":"Trends Cancer"},{"key":"2026021010301636000_2026.02.04.703648v1.64","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0891"},{"key":"2026021010301636000_2026.02.04.703648v1.65","doi-asserted-by":"crossref","unstructured":"Zhang S , Peng W , Wang H , Xiang X , Ye L , Wei X , et al. C1q(+) tumor-associated macrophages contribute to immunosuppression through fatty acid metabolic reprogramming in malignant pleural effusion. J Immunother Cancer. 2023;11(8).","DOI":"10.1136\/jitc-2023-007441"},{"key":"2026021010301636000_2026.02.04.703648v1.66","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-021-00911-1"},{"key":"2026021010301636000_2026.02.04.703648v1.67","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32255-7"},{"key":"2026021010301636000_2026.02.04.703648v1.68","doi-asserted-by":"crossref","unstructured":"Parsons A , Colon ES , Spasic M , Kurt BB , Swarbrick A , Freedman RA , et al. Cell Populations in Human Breast Cancers are Molecularly and Biologically Distinct with Age. Res Sq. 2024.","DOI":"10.1038\/s43587-025-00984-1"},{"key":"2026021010301636000_2026.02.04.703648v1.69","first-page":"e390464","article-title":"Early-Stage Triple-Negative Breast Cancer Journey: Beginning, End, and Everything in Between","volume":"43","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026021010301636000_2026.02.04.703648v1.70","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-3152-1"},{"key":"2026021010301636000_2026.02.04.703648v1.71","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181bb499f"},{"key":"2026021010301636000_2026.02.04.703648v1.72","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41523-020-0171-1","article-title":"Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer","volume":"6","year":"2020","journal-title":"NPJ Breast Cancer"},{"key":"2026021010301636000_2026.02.04.703648v1.73","doi-asserted-by":"publisher","DOI":"10.1172\/JCI90499"},{"key":"2026021010301636000_2026.02.04.703648v1.74","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3666"},{"key":"2026021010301636000_2026.02.04.703648v1.75","doi-asserted-by":"publisher","DOI":"10.4161\/onci.25789"},{"key":"2026021010301636000_2026.02.04.703648v1.76","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-2788"},{"key":"2026021010301636000_2026.02.04.703648v1.77","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2023.04.005"},{"issue":"11","key":"2026021010301636000_2026.02.04.703648v1.78","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/s41556-024-01508-6","article-title":"Solid tumour-induced systemic immunosuppression involves dichotomous myeloid-B cell interactions","volume":"26","year":"2024","journal-title":"Nat Cell Biol"},{"key":"2026021010301636000_2026.02.04.703648v1.79","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.04.007"},{"issue":"13","key":"2026021010301636000_2026.02.04.703648v1.80","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1158\/1078-0432.CCR-22-2657","article-title":"Intratumoral CD16+ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy","volume":"29","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026021010301636000_2026.02.04.703648v1.81","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-1300"},{"key":"2026021010301636000_2026.02.04.703648v1.82","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06685-2"},{"key":"2026021010301636000_2026.02.04.703648v1.83","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2022.04.008"},{"key":"2026021010301636000_2026.02.04.703648v1.84","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08257-4"},{"key":"2026021010301636000_2026.02.04.703648v1.85","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111769"},{"key":"2026021010301636000_2026.02.04.703648v1.86","doi-asserted-by":"publisher","DOI":"10.1038\/nature21409"},{"key":"2026021010301636000_2026.02.04.703648v1.87","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.08.005"},{"issue":"89","key":"2026021010301636000_2026.02.04.703648v1.88","doi-asserted-by":"crossref","first-page":"eadj5097","DOI":"10.1126\/sciimmunol.adj5097","article-title":"Cancer immunotherapy via synergistic coactivation of myeloid receptors CD40 and Dectin-1","volume":"8","year":"2023","journal-title":"Sci Immunol"},{"issue":"10","key":"2026021010301636000_2026.02.04.703648v1.89","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/s41551-025-01400-0","article-title":"Potentiating cancer immunotherapies with modular albumin-hitchhiking nanobody-STING agonist conjugates","volume":"9","year":"2025","journal-title":"Nat Biomed Eng"},{"key":"2026021010301636000_2026.02.04.703648v1.90","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0907"},{"key":"2026021010301636000_2026.02.04.703648v1.91","doi-asserted-by":"publisher","DOI":"10.1038\/nature19834"},{"issue":"4","key":"2026021010301636000_2026.02.04.703648v1.92","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","article-title":"CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial","volume":"31","year":"2025","journal-title":"Nat Med"},{"key":"2026021010301636000_2026.02.04.703648v1.93","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.02.048"},{"key":"2026021010301636000_2026.02.04.703648v1.94","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1283"},{"issue":"7","key":"2026021010301636000_2026.02.04.703648v1.95","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.ccell.2025.03.021","article-title":"ZEB2 is a master switch controlling the tumor-associated macrophage program","volume":"43","year":"2025","journal-title":"Cancer Cell"},{"key":"2026021010301636000_2026.02.04.703648v1.96","doi-asserted-by":"publisher","DOI":"10.1172\/JCI1112"},{"key":"2026021010301636000_2026.02.04.703648v1.97","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4096"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.02.04.703648","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:30:34Z","timestamp":1770748234000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2026.02.04.703648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":97,"URL":"https:\/\/doi.org\/10.64898\/2026.02.04.703648","relation":{},"subject":[],"published":{"date-parts":[[2026,2,6]]},"subtype":"preprint"}}